Cancer STEM cells drive Brain cancer

Dr. Weeks’ CommentL This is the update from Harvard Medical School  regarding how cancer STEM cells, until now only targeted by Practitioners of Corrective Cancer Care with safe and effective anti-inflammatory agents like powerful whole crushed seed products,  are driving brain cancer.  
November 4, 2016

It has become clear that cancer stem cells””cells within tumors that exhibit stem cell characteristics and can differentiate into other specialized types of cancer cells””have a role in the progression and treatment resistance of several types of tumors, most prominently blood system tumors like leukemia.

Several studies have supported a role for cancer stem cells in the aggressive brain tumors called glioblastoma, but those studies involved inducing human tumors to grow in mice and their relevance to cancer in humans has been questioned.

To more accurately reflect the mechanisms driving oligodendrogliomas, the researchers used RNA sequencing to study directly, on a single-cell level, gene expression in samples from six early-stage human tumors.

Their analysis of more than 4,000 individual tumor cells, the largest effort to date in brain tumors, finds three developmental categories of cancer cells””one resembling neural stem cells and two characterized by sets of genes indicting paths towards differentiation.

The authors then observed that only a subset of cancer stem cells in each patient was showing signs of proliferation, while all other cancer cells were not.

Importantly, these three developmental signatures were found in distinct genetic clones””cells with identical patterns of genetic mutations””of tumor cells.

“Finding that different subclones within tumors show the same developmental patterns suggests that developmental programs””whether in stem cells or differentiated cancer cells””set the context within which genetic evolution of oligodendroglioma occurs, which is key to supporting the cancer stem cell model,” said Suvà.

“Trying to understand as much as we can about genetic versus non-genetic determinants of tumor organization is key to our understanding of tumor propagation and to the design of new therapies. Our work suggests that targeting a specific stem cell phenotype, for example with immunotherapies, could be beneficial in patients with oligodendroglioma,” he said.

Leave a Comment

Your email address will not be published. Required fields are marked *